Literature DB >> 1254383

Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half-life of tolbutamide.

E Syvälahti, K Pihlajamäki, E Iisalo.   

Abstract

The effect of drugs used in the chemotherapy of tuberculosis on blood glucose, serum immunoreactive insulin and serum growth hormone, and on the half-life of tolbutamide, were studied in 16 patients with tuberculosis just before starting treatment and four weeks later using an intravenous tolbutamide test. The maximum fall of blood sugar was about 30% on both test occasions. The peak values of serum growth hormone before and after treatment (15.6+/-3.1 ng/ml and 17.3+/-2.9 ng/ml), and the maximum values of serum insulin before or after treatment (37.6+/-5.3muU/ml and 45.6+/-7.0 muU/ml) did not differ significantly from one another. The levels of serum insulin remained slightly higher in the test from 10 minutes onwards after treatment than before, but this was not associated with any particular tuberculostatic drug combination. The half-life of tolbutamide decreased by 43% and the serum concentration of tolbutamide decreased at 180 minutes by 30% and at 360 minutes by 49% after treatment in comparison with the pretreatment values in the patients receiving rifampicin in their drug combination. In patients receiving other tuberculostatic agents, no significant changes were observed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1254383

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  5 in total

Review 1.  Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

Authors:  J E Jackson; R Bressler
Journal:  Drugs       Date:  1981-10       Impact factor: 9.546

Review 2.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

3.  Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.

Authors:  M Niemi; K T Kivistö; J T Backman; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 4.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.

Authors:  Mikko Niemi; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.